DECISIO has fresh funding and a new board member. Photo via decisiohealth.com

A Houston-based digital health startup has officially closed its latest funding round and has a new member to its leadership to support the company's next phase.

DECISIO has appointed Major General Elder Granger to the company's board of directors. Dr. Granger is currently president and CEO of The 5Ps LLC, a healthcare, education, and leadership consulting organization.

"Dr. Granger joining our board provides enormous value and validation for our company moving forward," says Dr. John Holcomb, co-CEO and co-founder of DECISIO, says in a news release. "His expertise and leadership in the healthcare industry is a welcome addition to our esteemed group of Board of Directors."

Dr. Granger previously served as the deputy director of TRICARE Management Activity, a Department of Defense field activity responsible for operating the Military Health System as a fully integrated healthcare system providing care for 9.2 million beneficiaries worldwide. He also serves on the board of directors for Cerner Corp., Cigna Corp., and DLH Holdings Corp.

In February, the company officially closed its $18.5 million series B. DECISIO has raised $31.5 million since it was founded in 2013. The funding raised will go toward commercialization, continued product development, and operations growth.

Decisio is a virtual care monitoring software that's based on technology licensed from and developed at the University of Texas Health Science Center in Houston. Using real-time clinical surveillance with data visualization, the DECISIOInsight software can identify risk that helps clinicians make better patient care decisions virtually. In 2015, Decisio Health was approved by the Food and Drug Administration class II medical device, which made it the first FDA-cleared web-native software.

"Virtual Care is the next step beyond traditional telemedicine, which — for many years — was limited to having a teleconference or even just a phone call with a caregiver," Hancock previously told InnovationMap. "Now we can start sharing real-time clinical data with clinicians wherever they happen to be located."

DECISIO's flagship product is called InsightIQ, and earlier this month the company launched a new tool: EnvisionIQ, which provides templated real-time and customized compliance reports to improve operational efficiency.

Dr. Elder Granger previously oversaw the DoE's health care system. Photo courtesy

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”